This article discusses the validation of the SIE/SIES/GITMO consensus criteria, also known as the Ferrara criteria, for predicting early mortality and survival in acute myeloid leukemia (AML) patients treated with hypomethylating agents and venetoclax. The study collected data from AML patients who received this treatment and retrospectively applied the Ferrara criteria to evaluate their impact on patient outcomes. The results showed that being unfit for non-intensive chemotherapy was associated with shorter overall survival and increased early mortality in both newly diagnosed and relapsed/refractory patients. The study suggests that the Ferrara criteria can be used to identify AML patients who may not benefit from this treatment. [Extracted from the article]